Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Impact of Therapy Sequence on Survival Outcomes Among Patients with Relapsed or Refractory Mature T and NK Cell Neoplasms: A Global Retrospective Cohort Study

Mark N Sorial, Min Jung Koh, Leora Boussi, Jessy Xinyi Han, Luke Peng, Ijeoma Julie Eche-Ugwu, Rui Duan, Matthew M. Lei, Eliana Miranda, Carlos Chiattone, Robert Stuver, Steven M. Horwitz, Maria J. Fernandez Turizo, Sean McCabe, Mwanasha Hamuza Merrill, Eric Jacobsen, Jin Seok Kim, Yu Ri Kim, Jae Yong Cho, Hasmukh Jain, Manju Sengar, Thomas Eipe, Tanuja Shet, Shambhavi Singh, Uvette Lou, Hesham Raghib, Judith Gabler, Min Ji Koh, Carrie Van Der Weyden, Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine M. Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al Mansour, Josie Ford, Martina Manni, Massimo Federico, Owen A. O'Connor, Maria Elena Cabrera, Enrica Marchi, Changyu Shen, Devavrat Shah, Salvia Jain

Blood (2023) 142 (Supplement 1): 3080.

https://doi.org/10.1182/blood-2023-182341

Published: 2023

Journal Articles

Phase 1 Study of Autologous Sirpα-Low Macrophages (SIRPant-M) Administered By Intratumoral Injection Alone or in Combination with External-Beam Radiotherapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NCT05967416)

Paolo Strati, Tatyana Feldman, Christiane Querfeld, Salvia Jain, Nathanael McCurley, Rita Bàrcia, Koby Kidder, Jelle Kylstra

Blood (2023) 142 (Supplement 1): 4856.

https://doi.org/10.1182/blood-2023-175040

Published: 2023

Journal Articles

Novel Causal Inference Method Estimates Treatment Effects of Contemporary Drugs in a Global Cohort of Patients with Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms

Blood (2023) 142 (Supplement 1): 1703.

https://doi.org/10.1182/blood-2023-185881

Published: 2023

Journal Articles

Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial

Nathan Roberts, John Lister, N. Nora Bennani, Salvia Jain, Tammy Battaglia, Emily C. Ayers, Craig A. Portell, Michael E. Williams, Prem Batchala, Ipsita Pal, Owen A. O'Connor, John Sanil Manavalan, Enrica Marchi

Blood (2022) 140 (Supplement 1): 9425–9426.

https://doi.org/10.1182/blood-2022-170181

Published: 2022

Journal Articles

A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma - a Bridge to Transplant and an Effective Salvage for the Unfit

Matko Kalac, Salvia Jain, Constantine S. Tam, Mendel Goldfinger, Zhengrui Xiao, Francesca Montanari, Bryan D. Huber, Jennifer A. Kanakry, Owen A. O'Connor, Enrica Marchi

Blood (2022) 140 (Supplement 1): 9422–9424.

https://doi.org/10.1182/blood-2022-165165

Published: 2022

Journal Articles

KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 2253–2255.

https://doi.org/10.1182/blood-2022-162583

Published: 2022

Journal Articles

Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era

Blood (2022) 140 (Supplement 1): 10976–10978.

https://doi.org/10.1182/blood-2022-162944

Published: 2022

Journal Articles

TP63 Fusions Drive Enhancer Rewiring, Lymphomagenesis, and Dependence on EZH2

Blood (2022) 140 (Supplement 1): 1696–1697.

https://doi.org/10.1182/blood-2022-163368

Published: 2022

Journal Articles

Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1

Blood (2022) 139 (13): 2024–2037.

https://doi.org/10.1182/blood.2021014701

Published: 2022

Includes: Supplemental data

Journal Articles

Novel Single Agents Are Equivalent to Conventional Chemotherapy Inpatients with Relapsed and Refractory Mature T-Cell Lymphomas: A Meta-Analysis

Nazila Shafagati, Robert N. Stuver, Leora Boussi, Min Jung Koh, Allison Park, Paul Bain, Francine M. Foss, Changyu Shen, Salvia Jain

Blood (2021) 138 (Supplement 1): 1431.

https://doi.org/10.1182/blood-2021-150315

Published: 2021

Journal Articles

Comparative Analysis of Mature T-Cell and NK/T-Cell Lymphomas in Patients with and without HIV: Results from the NA-Accord and Complete Cohorts

Blood (2021) 138 (Supplement 1): 1380.

https://doi.org/10.1182/blood-2021-147837

Published: 2021

Journal Articles

Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma

Shira Orr, PhD, Marzia Capelletti, PhD MBBS, Haider Ghiasuddin, Dina Stroopinsky, PhD, Jessica Liegel, MD, Myrna Nahas, MD, Matthew Weinstock, MD, Adam Morin, Robin M. Joyce, MD, Salvia Jain, MD, Jon E. Arnason, MD, Maryam Rahimian, MD, Lina Bisharat, Shufen Meng, MD, Donald Kufe, MD, Jacalyn Rosenblatt, MD, David E. Avigan, MD

Blood (2019) 134 (Supplement_1): 392.

https://doi.org/10.1182/blood-2019-124768

Published: 2019

Journal Articles

Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas

Salvia Jain, Alexandria Van Scoyk, Elizabeth A. Morgan, Andrew Matthews, Kristen Stevenson, Gail Newton, Foster Powers, Anu Autio, Abner Louissaint, Jr, Guillemette Pontini, Jon C. Aster, Francis W. Luscinskas, David M. Weinstock

Blood (2019) 134 (17): 1430–1440.

https://doi.org/10.1182/blood.2019001744

Published: 2019

Includes: Supplemental data

Journal Articles

Targeted Inhibition of CD47-Sirp Alpha Requires Fc-Fc Gamma Receptor Interactions to Maximize Phagocytosis in T-Cell Lymphomas

Salvia Jain, MD, Alexandria Van Scoyk, Elizabeth A Morgan, MD, Andrew Matthews, MD, Kristen E. Stevenson, MS, Gail Newton, PhD, Anu K Autio, PhD, Marisa O. Peluso, MS, Rachel W O'Connor, BS, Alison M. Paterson, PhD, Pamela M. Holland, PhD, Francis W Luscinskas, PhD, David M Weinstock, MD

Blood (2018) 132 (Supplement 1): 339.

https://doi.org/10.1182/blood-2018-99-112986

Published: 2018

Journal Articles

Ex-Vivo Stimulation with DC/AML Fusion Vaccine in the Presence of Cytokines Leads to an Activated T Cell Memory Phenotype and Enhanced Cytotoxicity with Potential for Use As an Adoptive Cellular Therapy

Jessica Liegel, MD, Dina Stroopinsky, PhD, Lourdes M. Mendez, MD PhD, Malgorzata McMasters, MD, Haider Ghiasuddin, BA, Maryam Rahimian, MD, Myrna Nahas, MD, Matthew Weinstock, MD, Salvia Jain, MD, Marzia Capelletti, PhD MMSc, Lina Bisharat, MA, Adam Morin, BA, Shira Orr, PhD, Jacalyn Rosenblatt, MD, Donald Kufe, MD, David E. Avigan, MD

Blood (2018) 132 (Supplement 1): 2728.

https://doi.org/10.1182/blood-2018-99-119996

Published: 2018

Journal Articles

A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model

Dina Stroopinsky, PhD, Jessica Liegel, MD, Kathleen M. Mahoney, MD PhD, Jacalyn Rosenblatt, MD, Benjamin L. Ebert, MD PhD, Richard M. Stone, MD, Maryam Rahimian, MD, Myrna Nahas, MD, Shira Orr, PhD, Marzia Capelletti, PhD MMSc, Matthew Weinstock, MD, Salvia Jain, MD, Lina Bisharat, MA, Haider Ghiasuddin, BA, Adam Morin, BA, Donald Kufe, MD, Gordon J Freeman, PhD, David E. Avigan, MD

Blood (2018) 132 (Supplement 1): 1446.

https://doi.org/10.1182/blood-2018-99-120259

Published: 2018

Journal Articles

Role of Single Agent and Combination Chemotherapy Strategies in Relapsed/Refractory Peripheral T-Cell Lymphoma: Results from the Complete Registry

Robert Stuver, MD, Niloufer Khan, MD, Marc Schwartz, Mark Acosta, Massimo Federico, MD, Christian Gisselbrecht, Frederick Lansigan, MD, Lauren C. Pinter-Brown, MD, Barbara Pro, MD, Andrei R. Shustov, MD, Steven M. Horwitz, MD, Francine M. Foss, MD, Salvia Jain, MD

Blood (2018) 132 (Supplement 1): 2926.

https://doi.org/10.1182/blood-2018-99-112869

Published: 2018

Journal Articles

Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Blood (2018) 131 (25): 2836–2845.

https://doi.org/10.1182/blood-2017-05-780239

Published: 2018

Includes: Supplemental data

Journal Articles

Phase I/Ib Trial of the MUC1 Inhibitor GO-203-2C Alone and in Combination with Decitabine for Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 2659.

https://doi.org/10.1182/blood.V130.Suppl_1.2659.2659

Published: 2017

Journal Articles

MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia

Blood (2017) 129 (13): 1791–1801.

https://doi.org/10.1182/blood-2016-07-730614

Published: 2017

Includes: Supplemental data

NARROW

Impact of Therapy Sequence on Survival Outcomes Among Patients with Relapsed or Refractory Mature T and NK Cell Neoplasms: A Global Retrospective Cohort Study

Phase 1 Study of Autologous Sirpα-Low Macrophages (SIRPant-M) Administered By Intratumoral Injection Alone or in Combination with External-Beam Radiotherapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NCT05967416)

Novel Causal Inference Method Estimates Treatment Effects of Contemporary Drugs in a Global Cohort of Patients with Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms

Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial

A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma - a Bridge to Transplant and an Effective Salvage for the Unfit

KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas

Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era

TP63 Fusions Drive Enhancer Rewiring, Lymphomagenesis, and Dependence on EZH2

Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1

Novel Single Agents Are Equivalent to Conventional Chemotherapy Inpatients with Relapsed and Refractory Mature T-Cell Lymphomas: A Meta-Analysis

Comparative Analysis of Mature T-Cell and NK/T-Cell Lymphomas in Patients with and without HIV: Results from the NA-Accord and Complete Cohorts

Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma

Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas

Targeted Inhibition of CD47-Sirp Alpha Requires Fc-Fc Gamma Receptor Interactions to Maximize Phagocytosis in T-Cell Lymphomas

Ex-Vivo Stimulation with DC/AML Fusion Vaccine in the Presence of Cytokines Leads to an Activated T Cell Memory Phenotype and Enhanced Cytotoxicity with Potential for Use As an Adoptive Cellular Therapy

A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model

Role of Single Agent and Combination Chemotherapy Strategies in Relapsed/Refractory Peripheral T-Cell Lymphoma: Results from the Complete Registry

Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Phase I/Ib Trial of the MUC1 Inhibitor GO-203-2C Alone and in Combination with Decitabine for Acute Myeloid Leukemia

MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only